253 related articles for article (PubMed ID: 25770294)
21. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
23. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
24. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
26. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
30. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
31. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Jain N; Stock W; Zeidan A; Atallah E; McCloskey J; Heffner L; Tomlinson B; Bhatnagar B; Feingold J; Ungar D; Chao G; Zhang X; Qin Y; Havenith K; Kantarjian H; Wieduwilt MJ
Blood Adv; 2020 Feb; 4(3):449-457. PubMed ID: 32012214
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Kantarjian HM; Lioure B; Kim SK; Atallah E; Leguay T; Kelly K; Marolleau JP; Escoffre-Barbe M; Thomas XG; Cortes J; Jabbour E; O'Brien S; Bories P; Oprea C; Hatteville L; Dombret H
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):139-45. PubMed ID: 26775883
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
Herrera L; Bostrom B; Gore L; Sandler E; Lew G; Schlegel PG; Aquino V; Ghetie V; Vitetta ES; Schindler J
J Pediatr Hematol Oncol; 2009 Dec; 31(12):936-41. PubMed ID: 19875969
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
37. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19
Zheng Q; Wang Z; Zhang H; Huang Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Mol Oncol; 2017 May; 11(5):584-594. PubMed ID: 28306193
[TBL] [Abstract][Full Text] [Related]
38. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
[TBL] [Abstract][Full Text] [Related]
39. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
40. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]